Avid Bioservices Inc Net Income per Employee (CDMO), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Avid Bioservices Inc   (NASDAQ: CDMO)
 

Avid Bioservices Inc Net Income per Employee

CDMO's Quarterly Results, Trends, Rankings, Statistics
Avid Bioservices Inc recorded a cumulative net loss of $-152 million during 12 month ending in the second quarter 2025.
The Healthcare sector has seen employees of 151 other companies achieving higher income per employee. While Avid Bioservices Inc 's total ranking has deteriorated compared to the previous quarter from 2848 to 3547.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CDMO Net Income per Employee (Oct 31 2024)
II. Quarter		 (Jul 31 2024)
I. Quarter		 (Apr 30 2024)
IV. Quarter		 (Jan 31 2024)
III. Quarter		 (Oct 31 2023)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -409,838 -388,585 -379,388 -49,216 -31,784
CDMO's Total Ranking # 3547 # 2848 # 2227 # 2138 # 2269
Seq. Net Income Change - - - - -

CDMO Company Profile >> Back to CDMO Efficiency Comparisons >> Compare CDMO Net Income per Employee to its Competitors

CDMO Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 152
Healthcare Sector # 467
Overall Market # 3547

Net Income per Employee Statistics
High Average Low
$ 344,129 $ -44,082 $ -409,838
(Apr 30 2022)   (Oct 31 2024)




  News about Avid Bioservices Inc Income per employee

Avid Bioservices Announces Pricing of Private Placement of Convertible Notes.

Avid Bioservices, Inc. (NASDAQ:CDMO), a renowned biologics contract development and manufacturing organization (CDMO), revealed the successful pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the 2029 Notes), as announced on March 6, 2024. In an effort to raise capital, the company entered into private placement purchase agreements with various qualified institutional buyers, in accordance with Rule 144A under the Securities Act of 1933, as amended. The offering, subject to customary closing conditions, is expected to conclude on March 12, 2024.
This strategic move demonstrates Avid Bioservices commitment to continue expanding and growing its capabilities within the biologics sector. By securing $160 million through the issuance of Convertible Senior Notes, the company aims to strengthen its financial position and support its ongoing research and development efforts.




Companies with similar Income per Employee for 12 month ending Oct 31 2024, within Healthcare Sector Income per Employee Income 12 month ending Oct 31 2024Number of Employees Oct 31 2024


Date modified: 2026-08-29T17:15:55+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.